Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer

(2017) Lara A. Dunn et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

(2017) Petr Szturz et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials

(2017) Bum Jun Kim et al.   Oncotarget

AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors

(2017) Renato José Silva-Oliveira et al.   Oncotarget

Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells

(2017) Muzafar A. Macha et al.   Oncotarget

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

(2017) et al.   Cancers

Epidermal Growth Factor Receptor Inhibitors: Coming of Age

(2017) Amit Mahipal et al.   Cancer Control

APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

(2016) Christophe Deben et al.   CANCER LETTERS

HER2 and HER3 in HPV+ and HPV- HNSCC--Letter

(2016) J.-P. Machiels et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

(2016) M. Iida et al.   MOLECULAR CANCER THERAPEUTICS

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

(2016) T. N. Beck et al.   MOLECULAR CANCER THERAPEUTICS

Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin

(2016) ROMAN C. BRANDS et al.   Molecular Medicine Reports

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma

(2016) Christine H. Chung et al.   ORAL ONCOLOGY

Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer

(2016) I. De Pauw et al.   PHARMACOLOGY & THERAPEUTICS

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

(2016) Jérôme Fayette et al.   Frontiers in Oncology

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies

(2015) N. I. Pollock et al.   CLINICAL CANCER RESEARCH

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

(2015) Jean-Pascal H Machiels et al.   LANCET ONCOLOGY

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo

(2015) Natalie R. Young et al.   Targeted Oncology

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status

(2015) Florence Huguet et al.   Targeted Oncology

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†

(2014) T. Y. Seiwert et al.   ANNALS OF ONCOLOGY

Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

(2014) Carolien Boeckx et al.   CANCER LETTERS

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

(2014) Tanguy Y. Seiwert et al.   CLINICAL CANCER RESEARCH

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

(2014) Mari Iida et al.   Molecular Cancer

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy

(2014) M Pogorzelski et al.   Cell Death & Disease

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

(2013) Nikolaos Ioannou et al.   BMC CANCER

Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)

(2013) Roger B. Cohen   CANCER TREATMENT REVIEWS

Statistical analysis of human papillomavirus in a subset of upper aerodigestive tract tumors

(2013) Hongwei Liu et al.   JOURNAL OF MEDICAL VIROLOGY

Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

(2013) C. Boeckx et al.   ONCOLOGIST

Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines

(2013) Remco Nagel et al.   ORAL ONCOLOGY

The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors

(2012) An Wouters et al.   CURRENT PHARMACEUTICAL DESIGN

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies

(2012) Lisa Licitra et al.   EUROPEAN JOURNAL OF CANCER

Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region

(2012) Hisham Mehanna et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses

(2012) Xuanming Yang et al.   MOLECULAR THERAPY

Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays

(2012) Ridha Limame et al.   PLoS One

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a NovelIn VivoModel of Acquired Cetuximab Resistance

(2011) Kelly M. Quesnelle et al.   CLINICAL CANCER RESEARCH

Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

(2011) Mikiko Takikita et al.   Journal of Translational Medicine

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

(2010) L. Licitra et al.   ANNALS OF ONCOLOGY

The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1  and Bcl-2 and Activating the Beclin 1/hVps34 Complex

(2010) X. Li et al.   CANCER RESEARCH

HIF-2 -mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia

(2010) X. Wang et al.   CARCINOGENESIS

Combination of Anti-IGF-1R Antibody A12 and Ionizing Radiation in Upper Respiratory Tract Cancers

(2010) Oliver Riesterer et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

HPV-associated head and neck cancer: a virus-related cancer epidemic

(2010) Shanthi Marur et al.   LANCET ONCOLOGY

Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse

(2010) Ira Skvortsova et al.   RADIOTHERAPY AND ONCOLOGY

Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model

(2009) An Wouters et al.   CANCER LETTERS

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck

(2009) Ezra Eddy Wyssam Cohen et al.   ORAL ONCOLOGY

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

(2008) H. Michael Shepard et al.   JOURNAL OF CLINICAL INVESTIGATION

Requirement of hypoxia-inducible factor-1  down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab

(2008) X. Li et al.   MOLECULAR CANCER THERAPEUTICS

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE